Chromoblastomycosis caused by Fonsecaea pedrosoi: The first molecularly confirmed case from Türkiye.

Diagn Microbiol Infect DisApr 9, 2026 (epub)

Büşra Çalışır, Sezen Yusuf, Seçil Ak Aksoy et al.

✦ AI-curated · Sources linked

Case in brief

A patient in Türkiye presented with pruritic, sclerotic, purplish lesions on the right forearm. Biopsy showed characteristic muriform cells, and culture grew a dematiaceous fungus. Internal transcribed spacer sequencing identified the isolate as Fonsecaea pedrosoi, confirming chromoblastomycosis. The patient received itraconazole; at 12-month follow-up, the lesions had regressed significantly.

What made this case unusual

The report documents molecular confirmation of F. pedrosoi as the cause of chromoblastomycosis in Türkiye, described by the authors as the first such case from the country.

Diagnostic / clinical pearl

In suspected chromoblastomycosis, characteristic muriform cells on histopathology can support diagnosis; culture with ITS sequencing can identify the causative fungus.

Why it matters

The case highlights recognition of F. pedrosoi infection in a country described as non-endemic.

Source

Published in Diagn Microbiol Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.